Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

  • The PLOS ONE Staff
  • Article
  • Metrics
  • Comments
  • Media Coverage

Notice of Republication

This article was republished on September 15, 2014, to correct typesetting errors involving missing minus symbols throughout the text and tables. The publisher apologizes for these errors. Please download this article again to view the article. The originally published, uncorrected article and the republished, corrected article are provided here for reference.

Supporting Information

File S1.

Originally published, uncorrected article

https://doi.org/10.1371/journal.pone.0110069.s001

PDF

File S2.

Republished, corrected article

https://doi.org/10.1371/journal.pone.0110069.s002

PDF

Reference

  1. 1. Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, et al. (2014) Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE 9(8): e105638

Citation: The PLOS ONE Staff (2014) Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE 9(9): e110069. https://doi.org/10.1371/journal.pone.0110069

Published: September 30, 2014

Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.